focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,757.00
Bid: 1,756.50
Ask: 1,757.50
Change: 1.00 (0.06%)
Spread: 1.00 (0.057%)
Open: 1,743.50
High: 1,759.00
Low: 1,740.50
Prev. Close: 1,756.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Tech shines but tepid trade elsewhere

Wed, 26th Apr 2023 17:03

(Alliance News) - European equities closed lower on Wednesday, with lingering banking sector worries hurting sentiment, while tech stocks outperformed wider markets in New York after well-received earnings overnight.

In London, the FTSE 100 was hurt by share price falls for pharmaceutical stocks and building materials company CRH. Housebuilders and banking shares climbed, however.

The FTSE 100 index ended down 38.49 points, or 0.5%, at 7,852.64. The FTSE 250 fell just 7.42 points to 19,207.97. The AIM All-Share closed down 2.42 points, or 0.3%, at 821.84.

The Cboe UK 100 ended down 0.6% at 785.31, the Cboe UK 250, however, added 0.2% at 16,842.98. The Cboe Small Companies lost 0.2% at 13,293.67.

Stocks in New York were mixed on Wednesday. The Dow Jones Industrial Average was down 0.1%, while the S&P 500 index was up 0.3%, and the Nasdaq Composite surged 1.2%.

The tech-focused Nasdaq was an outlier in an otherwise tepid day for major indices.

Helping to boost the Nasdaq was a 7.8% share price rise for Microsoft.

It reported late Tuesday increased revenue and earnings in its financial third quarter, boosted by solid growth in its cloud division.

However, it received a blow on Wednesday after the UK's antitrust watchdog prevented its deal to acquire video game maker Activision Blizzard. Activision was down 11% in New York.

Microsoft said it would appeal the decision, and said the Competition & Markets Authority's decision reflects a "flawed understanding of this market and the way relevant cloud technology actually works".

The CMA said deal was blocked to "protect innovation and choice in cloud gaming".

In European equities on Wednesday, the CAC 40 in Paris closed down 0.9%, while the DAX 40 in Frankfurt ended down 0.5%.

"For today, the luxury sector appears to be seeing some profit-taking with Kering lower along with LVMH, Hermes, and Burberry weighing on the wider market, helping to push the CAC 40 sharply lower.

The FTSE 100 is also under pressure with the weakness very much broad-based across various sectors, with defensives feeling the pressure along with cyclicals, with health care a particular drag," CMC Markets analyst Michael Hewson commented.

In Paris, LVMH and Hermes each lost 1.6% and Kering gave back 2.3%. The latter late Tuesday reported first-quarter sales growth, though the Gucci owner's progress fell well short from growth seen from its peers. In London, Burberry fell 1.9%.

GSK and AstraZeneca lost 4.0% and 3.9%. The former reported a slip in quarterly sales on Wednesday. Astra reports on Thursday.

GSK said its top-line shrunk by 3.3%, reflecting less Covid-19 solution sales compared to the previous year.

Also hurting the FTSE 100, CRH fell 3.3%. It backed its half-year outlook but noted a challenging environment in Europe.

The building materials company said that reported sales in the first quarter of 2023 were up 7% year-on-year.

However, the company expects a more challenging backdrop in Europe, driven by continued inflationary pressures and some slowdown in the new-build residential sector.

Reckitt fell 2.6%. The consumer goods firm reported that price hikes supported its first-quarter outturn, though volumes slid.

The company said volumes fell 4.5% on-year in the first quarter of 2023, though it logged price/mix improvements of 12%. Reckitt said total net revenue in the first quarter rose 14% year-on-year to GBP3.92 billion from GBP3.42 billion a year earlier, or 7.9% on a life-for-like basis.

Unilever fell 0.9% in a negative read across. It reports a first-quarter trading statement on Thursday.

Housebuilders were on the up, however, lifted by an encouraging update from Persimmon. Persimmon closed up 5.1%.

The housebuilder said it expects to reach the top end of its 2023 expectations, despite a drop in sales in the first quarter on an annual basis.

Numbers suggest that the housing market has picked up from the fourth quarter, however.

It reported net private sales per outlet of 0.62, down 37% from 0.98 a year ago, but up from 0.30 in the final quarter of 2022.

The firm noted that forward sales also dropped on a yearly basis to GBP1.7 billion, 30% less than GBP2.4 billion the year prior, but up compared to GBP1.0 billion in the final quarter of 2022.

Persimmon said it expects full-year new home completions at the top end of its 8,000-9,000 guidance, "if sales rates continue around the level seen year to date".

Crest Nicholson and Redrow climbed 7.0% and 4.5%, respectively, in a positive read-across.

Standard Chartered added 2.8% on improved first-quarter earnings, bolstered by rate hikes.

The Asia-focused bank reported pretax profit of USD1.81 billion, up 21% from USD1.49 billion year-on-year.

Operating income climbed 6.2% to USD4.56 billion from USD4.29 billion. This was helped by net interest income rising 13% year-on-year to USD2.01 billion from USD1.78 billion, as it benefited from rising interest rates.

In addition, the company said it plans to return "in excess" of USD5 billion to shareholders by 2024.

Shares in banking sector peer Barclays, which reports on Thursday, climbed 1.7%.

Elsewhere in London, Warpaint added 7.1%.

The cosmetics supplier, which owns W7 and Technic makeup brands, said pretax profit multiplied in 2022 to GBP7.7 million from GBP3.7 million in 2021, driven by a 28% increase in revenue to GBP64.1 million from GBP50.0 million.

Looking ahead, Warpaint said trading has remained strong so far in 2023. Revenue in the first quarter was GBP18.5 million, up 40% from GBP13.2 million a year before, while margin improved on the 2022 full-year result.

The pound was quoted at USD1.2472 late Wednesday afternoon in London, higher compared to USD1.2404 at the London equities close on Tuesday. The euro stood at USD1.1046, higher against USD1.0983. Against the yen, the dollar was trading at JPY133.54, lower compared to JPY133.98.

The dollar suffered as Federal Reserve tightening expectations eased, though a hike next week still looks likely.

Fed tightening expectations eased after poor results from First Republic Bank reminded markets of the stress being felt by some US regional banks.

According to the CME FedWatch tool, there is an 81% chance that the central bank lifts rates by 25 basis points to a range of 5.00%-5.25% on Wednesday next week. The Fed is expected to pause hikes thereafter.

Still to come on Wednesday are results from Facebook owner Meta Platforms. Online retailer Amazon and pharmaceutical firm Merck & Co report on Thursday.

Aside from updates from AstraZeneca, Barclays and Unilever, the UK corporate diary has annual results from grocer Sainsbury's and a trading statement from advertising company WPP on Thursday.

The economic calendar has a US gross domestic product reading at 1330 BST.

Brent oil was quoted at USD80.29 a barrel late Wednesday, down from USD80.52 late Tuesday. Gold was quoted at USD1,995.53 an ounce, up against USD1,987.63.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
16 Apr 2024 09:17

GSK meningococcal vaccine accepted by US FDA for review

(Sharecast News) - GSK announced on Tuesday that its five-in-one meningococcal ABCWY (MenABCWY) vaccine candidate had been accepted for regulatory review by the US Food and Drug Administration (FDA).

Read more
16 Apr 2024 08:59

GSK's latest meningitis vaccine accepted for review by US regulator

(Alliance News) - GSK PLC on Tuesday said it has made progress in the development of its newest candidate, which combines the strengths of two other vaccines in its portfolio into one bacteria-fighting inoculation.

Read more
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
9 Apr 2024 11:45

Pfizer RSV shot meets goals in trial of high-risk adults under age 60

April 9 (Reuters) - Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the age of 60 similar to that in older adults, for whom the shot is already approved.

Read more
8 Apr 2024 09:13

LONDON BROKER RATINGS: Wizz Air raised; HSBC cuts Rentokil to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
4 Apr 2024 13:08

UK dividends calendar - next 7 days

Friday 5 April 
BBGI Global Infrastructure SAdividend payment date
Molten Ventures PLCdividend payment date
Pennon Group PLCdividend payment date
Real Estate Credit Investments Ltddividend payment date
Regional REIT Ltddividend payment date
Rights & Issues Investment Trust PLCdividend payment date
Sylvania Platinum Ltddividend payment date
Titon Holdings PLCdividend payment date
Triple Point Energy Transition PLCdividend payment date
Monday 8 April 
Alumasc Group PLCdividend payment date
LondonMetric Property PLCdividend payment date
Redrow PLCdividend payment date
Tuesday 9 April 
CT Global Managed Portfolio Trust PLCdividend payment date
Downing Strategic Micro-Cap Investment Trust PLCdividend payment date
Dunelm Group PLCspecial dividend payment date
Hays PLCdividend payment date
Renishaw PLCdividend payment date
Safestore Holdings PLCdividend payment date
Wednesday 10 April 
Assura PLCdividend payment date
Primorus Investments PLCspecial dividend payment date
Wilmington PLCdividend payment date
Thursday 11 April 
Amedeo Air Four Plus Ltdex-dividend payment date
Athelney Trust PLCdividend payment date
Aviva PLCex-dividend payment date
Balanced Commercial Property Trust Ltdex-dividend payment date
Barratt Developments PLCex-dividend payment date
Begbies Traynor Group PLCex-dividend payment date
Bioventix PLCex-dividend payment date
Blackfinch Spring VCT PLCex-dividend payment date
BlackRock Latin American Investment Trust PLCex-dividend payment date
Caledonia Mining Corpex-dividend payment date
Capital & Regional PLCex-dividend payment date
Chesnara PLCex-dividend payment date
Colefax Group PLCdividend payment date
CT Private Equity Trust PLCex-dividend payment date
Downing Strategic Micro-Cap Investements Trust PLCex-dividend payment date
Driver Group PLCdividend payment date
F&C Investment Trust PLCex-dividend payment date
Foxtons Group PLCex-dividend payment date
Grafton Group PLCex-dividend payment date
GSK PLCdividend payment date
Harbour Energy PLCex-dividend payment date
Hargreaves Services PLCdividend payment date
Howden Joinery Group PLCex-dividend payment date
Hunting PLCex-dividend payment date
i3 Energy PLCex-dividend payment date
International Personal Finance PLCex-dividend payment date
International Public Partnerships Ltdex-dividend payment date
ITV PLCex-dividend payment date
Johnson Service Group PLCex-dividend payment date
JPMorgan Asia Growth & Income PLCex-dividend payment date
JPMorgan Japan Small Cap Growth & Income PLCex-dividend payment date
Just Group PLCex-dividend payment date
Kenmare Resources PLCex-dividend payment date
Kerry Group PLCex-dividend payment date
Kings Arms Yard VCT PLCex-dividend payment date
Law Debenture Corp PLCdividend payment date
Lloyds Banking Group PLCex-dividend payment date
Lowland Investment Cos PLCex-dividend payment date
Luceco PLCex-dividend payment date
Man Group PLCex-dividend payment date
Manchester & London Investement Trust PLCex-dividend payment date
Marble Point Loan Financing Ltdex-dividend payment date
Mercantile Investment Trust PLCex-dividend payment date
Mobius Investment Trust PLCex-dividend payment date
MTI Wireless Edge Ltddividend payment date
North American Income Trust PLCex-dividend payment date
Northamber PLCex-dividend payment date
Octopus Apollo VCT PLCex-dividend payment date
Phoenix Group Holdings PLCex-dividend payment date
Reckitt Benckiser Group PLCex-dividend payment date
Ricardo PLCdividend payment date
Savills PLCex-dividend payment date
Schroder Asian Total Return Investment Cos PLCex-dividend payment date
Schroder European Real Estate Investment Trust PLCex-dividend payment date
Scottish American Investment Cos PLCdividend payment date
Smurfit Kappa Group PLCex-dividend payment date
Softcat PLCex-dividend payment date
Somero Enterprises Incex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
Synectics PLCex-dividend payment date
TP ICAP Group PLCex-dividend payment date
Trifast PLCdividend payment date
TT Electronics PLCex-dividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.